CYP 3A proteins are expressed in human neutrophils and lymphocytes but are not induced by rifampicin

Life Sciences

Volumn 64, Issue 8, 1999, Pages 643-653

  Stärkel, Peter ^a   Sempoux, Christine ^a   Van den Berge, Véronique ^a   Stevens, Martine ^a   De Saeger, Christine ^a   Desager, Jean Pierre ^a   Horsmans, Yves ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

6 hydroxycortisol; Cytochrome P 450 3A; Lymphocytes; Polymorphic neutrophils; Rifampicin

Indexed keywords

CYTOCHROME P450; RIFAMPICIN;

ADULT; ARTICLE; DENSITOMETRY; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LYMPHOCYTE; MALE; NEUTROPHIL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ADULT; ANTIBODIES, MONOCLONAL; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CELL SEPARATION; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; CYTOPLASM; ENZYME INDUCTION; FEMALE; HUMANS; HYDROCORTISONE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES; MALE; MIDDLE AGED; MOLECULAR WEIGHT; NEUTROPHILS; OXIDOREDUCTASES, N-DEMETHYLATING; RIFAMPIN; TIME FACTORS;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0033556408     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(98)00606-7     Document Type: Article

References (22)

1. D.R. Neslon, T. Kamataki, D.J. Waxman, F.P. Guengerich, R.W. Estabrook, R. Feyerlisen, F.J. Gonzalez, M.J. Coon, I.C. Gunsalus, O. Gotoh, K. Okuda, D.W. Nebert, DNA Cell. Biol. 12 1-51 (1993).
2. D.R. Nelson, L. Koymans, T. Kamataki, J.J. Stegeman, R. Feyereisen, D.J. Waxman, M.R. Waterman, O. Gotoh, M.J. Coon, R.W. Estabrook, I.C. Gunsalus, D.W. Nebert, Pharmacogenetics 6 1-42 (1996).
3. F.P. Guengerich, Chem. Res. Toxicol. 4 391-407 (1991).
4. T. Shimada, F.P. Guengerich. Proc. Natl. Acad. Sci. USA 86 462-465 (1989).
5. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, F.P. Guengerich, J. Pharmacol. Exp. Ther. 270 414-423 (1994).
6. J.C. Kolars, K.S. Lown, P. Schmiedlin-Ren, M. Ghosh, C. Fang, S.A. Wrighton, R.M. Merion, P.B. Watkins, Pharmacogenetics 4 247-259 (1994).
7. B.D. Haehner, J.C. Gorski, M. Vandenbranden, S.A. Wrighton, S.K. Janardan, P.B. Watkins, S.D. Hall, Mol. Pharmacol. 50 52-59 (1996).
8. D.R. Krishna, U. Klotz, Clin. Pharmacokinet. 26 144-160 (1994).
9. G.I. Murray, T.S. Barnes, H.F. Sewell, S.W. Ewen, W.T. Melvin, M.D. Burke, Br. J. Clin. Pharmacol 25 465-475 (1988).
10. S.K. Janardan, K.L. Lown, P. Schmiedlin-Ren, K.E. Thummel, P.B. Watkins, Pharmacogenetics 6 379-385 (1996).
11. P.B. Watkins, Pharmacogenetics 4 171-184 (1994).
12. K.S. Lown, J.C. Kolars, K.E. Thummel, J.L. Barnett, K.L. Kunze, S.A. Wrighton, P.B. Watkins, Drug. Metab. Dispos. 22 947-955 (1994).
13. Y. Horsmans, J.P. Desager, C. Harvengt, Pharmacol. Toxicol. 71 258-261 (1992).
14. C. Ged, U.M. Rouillon, I. Pichard, J. Combalbert, N. Bressot, P. Bories, H. Michel, P. Beaune, P. Maurel, Br. J. Clin. Pharmacol. 28 373-387 (1989).
15. P.H. Beaune, P. Kremers, F. Letawe-Grougon, J.E. Gielen, Biochem. Pharmacol. 34 3547-3552 (1985).
16. Y. Horsmans, M. Stevens, A. Geubel, C. Harvengt, J. Rahier, Liver 12 344-350 (1992).
17. N. Finnström, G. Smith, A. Rane, C.R. Wolf, ISSX Proceedings 11 79 (abstract) (1997).
18. V. Ribrag, M. Massaad, F. Janot, J. Morizet, A. Grouyette, G.G. Chalot, Leuk-Lymphoma 18 303-310 (1995).
19. T.A. Kocarek, E.G. Schuetz, S.L. Storm, R.A. Fisher, P.S. Guzelian, Drug. Metab. Dispos. 23 415-421 (1995).
20. J.C. Kolars, P. Schmiedlin-Ren, J.D. Schmetz, C. Fang, P.B. Watkins, J. Clin. Invest. 90 1871-1878 (1992).
21. B.G. Lake, S.E. Ball, A.B. Renwick, J.M. Tredger, J. Kao, J.A. Beamand, R.J. Price, Xenobiotica 27 1165-1173 (1997).
22. K. Villikka, K.T. Kivisto, J.T. Backman, K.T. Olkkola, P.J. Neuvonen, Clin. Pharmacol. Ther. 61 8-14 (1997).